All 13th-series stock acquisition rights were acquired and canceled. No impact on current period results. For the monthly exercise status, of 40,000 shares granted, 81 shares were exercised, and unexercised rights decreased to 7,938.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4576","jir_company_name":"D. Western Therapeutics Institute, Inc.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-09-29","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/09\/4576-20260929-01.pdf","jir_short_summary":"All 13th-series stock acquisition rights were acquired and canceled. No impact on current period results. For the monthly exercise status, of 40,000 shares granted, 81 shares were exercised, and unexercised rights decreased to 7,938.","jir_summary":"### Completion of Acquisition and Cancellation of Stock Acquisition Rights\nBased on the board resolution held on July 15, 2025, the Company acquired and canceled all of the 13th-series stock acquisition rights it had issued. The acquisition date was September 29, 2026; the total acquired quantity was 7,938 pieces at 52 yen per right, totaling 412,776 yen. The number of remaining rights after cancellation is 0 pieces. The Company states there is no impact on the current period's financial results.\n\n### Monthly Exercise Status and Outlook\nFor the month, of the 40,000 shares granted in the target month, 81 shares were exercised, resulting in an exercise ratio of 0.40% relative to granted shares (unexercised rights decreased from 8,338 shares to 7,938 shares). Compliance with exercise restrictions was also noted, and overall the dilution impact on the market is considered limited. Future plans or additional scheduled exercises are stated as Unknown.","jir_financial_highlights":"Acquisition amount\/Quantity: 7,938 pieces (52 yen per stock acquisition right (total 412,776 yen))\nRemaining stock acquisition rights after cancellation: 0 pieces (Cancellation completed)\nMonthly exercise status: 40,000 shares granted, 81 shares exercised (Exercise ratio 0.40%, exercise rate relative to total issued shares 0.09%)\nTotal issued shares: 57,559,412 shares (Unexercised rights decreased from 8,338 shares to 7,938 shares)","jir_category":"","jir_hashtags":"#StockAcquisitionRights, #EquityReport, #ExerciseStatus","jir_key_figures":"Acquired quantity: 7,938 pieces\nRemaining after cancellation: 0 pieces\nTotal amount: 412,776 yen\nExercise ratio: 0.40%\nUnexercised rights: 7,938 pieces (decreased from 8,338 pieces at the end of the previous month)","jir_meta_title":"D. Western Therapeutics Institute, Inc. Completes Acquisition and Cancellation of 13th Stock Acquisition Rights\uff5cSeptember 2026","jir_meta_description":"D. Western Therapeutics Institute, Inc. has completed the full acquisition and cancellation of the 13th-series stock acquisition rights. Discloses September 2026 monthly exercise status and movement in unexercised rights. No impact on current period results.","jir_og_title":"D. Western Therapeutics Institute, Inc. Completes Acquisition and Cancellation of Stock Acquisition Rights","jir_og_description":"Completed acquisition and cancellation of the 13th-series stock acquisition rights. Reports monthly exercise status and movement in unexercised rights. No impact on financial results.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":59943,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"share_cancellation","footnotes":""},"sector":[],"importance":[],"class_list":["post-124315","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n